A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?

Chinese Medicine

Chris J Bushe¹  Nicola Savill¹ 

[1] Medical Department, Eli Lilly and Company Ltd, Lilly House, Priestley Road, Basingstoke, Hants, RG24 9NL, UK

关键词: SIGN;    NICE;    drug safety;    summary of product characteristics;    guidelines;    ADHD;   

Others  :  791484
DOI  :  10.1186/1753-2000-6-2

 received in 2011-07-12, accepted in 2012-01-10,  发布年份 2012

【 摘 要 】

Background

The safety of paediatric medications is paramount and contraindications provide clear pragmatic advice. Further advice may be accessed through Summaries of Product Characteristics (SPCs) and relevant national guidelines. The SPC can be considered the ultimate independent guideline and is regularly updated. In 2008, the authors undertook a systematic review of the SPC contraindications of medications licensed in the United Kingdom (UK) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). At that time, there were fewer contraindications reported in the SPC for atomoxetine than methylphenidate and the specific contraindications varied considerably amongst methylphenidate formulations. In 2009, the European Medicines Agency (EMA) mandated harmonisation of methylphenidate SPCs. Between September and November 2011, there were three changes to the atomoxetine SPC that resulted in revised prescribing information. In addition, Clinical Guidance has also been produced by the National Institute for Health and Clinical Excellence (NICE) (2008), the Scottish Intercollegiate Guidelines Network (SIGN) (2009) and the British National Formulary for Children (BNFC).

Methods

An updated systematic review of the Contraindications sections of the SPCs of all medications currently licensed for treatment of ADHD in the UK was undertaken and independent statements regarding contraindications and relevant warnings and precautions were then compared with UK national guidance with the aim of assessing any disparity and potential areas of confusion for prescribers.

Results

As of November 2011, there were seven medications available in the UK for the treatment of ADHD. There are 15 contraindications for most formulations of methylphenidate, 14 for dexamfetamine and 5 for atomoxetine. Significant differences exist between the SPCs and national guidance part due to the ongoing reactive process of amending the former as new information becomes known. In addition, recommendations are made outside UK SPC licensed indications and a significant contraindication for methylphenidate (suicidal behaviours) is missing from both the NICE and SIGN guidelines. Particular disparity exists relating to monitoring for suicidal and psychiatric side effects. The BNFC has not yet been updated in line with the European Union (EU) Directive on methylphenidate; it does not include any contraindications for atomoxetine but describes contraindications for methylphenidate that are no longer in the SPC.

Conclusion

Clinicians seeking prescribing advice from critical independent sources of data, such as SPCs and national guidelines, may be confused by the disparity that exists. There are major differences between guidelines and SPCs and neither should be referred to in isolation. The SPC represents the most relevant source of safety data to aid prescribing of medications for ADHD as they present the most current safety data in line with increased exposure. National guidelines may need more regular updates.

【 授权许可】

   
2012 Savill and Bushe; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Attention Deficit Hyperactivity Disorder: Diagnosis and management of ADHD in children, young people and adults: NICE Clinical Guideline 72. 2008.
• [2]Polanczyk G, De Lima M, Lessa Horta B, Biederman J, Rohde Augusto: The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis. Am J Psychiatry 2007, 164:942-948.
• [3]National Institute for Health and Clinical Excellence: Methylphenidate, atomoxetine and dexamfetamine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13 Technology Appraisal 98 2006.
• [4]McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, De Soysa R, Taylor E, Williams T, Wong ICK: Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. British J Psych 2009, 194:273-277.
• [5]European Commission: Notice to Applicants. A Guideline on Summary of Product Characteristics (SmPC). 2009. Revision 2
• [6]European Medicines Agency: Committee for medicinal products for human use (CHMP). Guideline on conduct of pharmacovigilance for medicines used by the paediatric population. 2007.
• [7]U.S, Department of Health and Human Services Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for Industry Development and Use of Risk Minimization Action Plans. 2005.
• [8]Savill N, Bushe C: A systematic review of the contra-indications in the Summary of Product Characteristics for drugs licensed for ADHD in the UK. Poster presentation at the 16th European Congress of Psychiatry, Nice, France 2008.
• [9]European Medicines Agency Press Release: European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidate-containing medicines in the EU. 2009.
• [10]European Medicines Agency: Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. 2009.
• [11]Scottish Intercollegiate Guidelines Network: Management of attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline (number 112) 2009.
• [12]electronic Medicines Compendium [http:/ / www.medicines.org.uk/ EMC/ medicine/ 14482/ SPC/ Strattera++10mg%2c+18mg%2c+25mg%2c+ 40mg%2c+60mg+or+80mg+hard+capsules. / accessed 30th November 2011] webcite
• [13]electronic Medicines Compendium [http:/ / www.medicines.org.uk/ EMC/ medicine/ 8382/ SPC/ Concerta+XL+18+mg+-+36+mg+prolonged +release+tablets/ accessed 30th November 2011] webcite
• [14]electronic Medicines Compendium [http:/ / www.medicines.org.uk/ EMC/ medicine/ 19549/ SPC/ Concerta+XL+27+mg+prolonged-release +tablets/ accessed 30th November 2011] webcite
• [15]electronic Medicines Compendium [http:/ / www.medicines.org.uk/ EMC/ medicine/ 19510/ SPC/ Medikinet+XL/ accessed 30th November 2011] webcite
• [16]electronic Medicines Compendium [http:/ / www.medicines.org.uk/ EMC/ medicine/ 1316/ SPC/ Ritalin/ accessed 30th November 2011] webcite
• [17]electronic Medicines Compendium [http:/ / www.medicines.org.uk/ EMC/ medicine/ 19664/ SPC/ Medikinet+Tablets/ accessed 30th November 2011] webcite
• [18]Dexamfetamine Sulphate 5 mg Tablets, Summary of Product Characteristics, March 2010 Auden Mackenzie
• [19]BNFC.org. British National Formulary for Children 2010-2011
• [20]Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S: Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007, 21(1):10-41.
• [21]Department of Health and Human Services Food and Drug Administration: Public Law 110-85. Title V--Best Pharmaceuticals for Children Act of 2007, Food and Drug Administration Amendments Act of 2007. [http:/ / frwebgate.access.gpo.gov/ cgi-bin/ getdoc.cgi?dbname=110_cong_public_l aws&docid=f:publ085.110.pdf] webcite
• [22]Regulation (EC) No 1901/of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004
• [23]European Medicines Agency: European network of paediatric research. Recognition criteria for self assessment 2010.
• [24]Bangs M, Sitra Tauscher-Wisniewski, Polzer J, Zhang Shuyu DVM, Acharya N, Desaiah D, Allen AJ: Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine. J Am Acad Child Adolesc Psychiatry 2008, 47(2):209-218.
• [25]Waxmonski JG, Waschbusch DA, Pelham WE, Draganac-Cardona L, Rotella B, Ryan L: Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2010, 71(11):1535-51.
• [26]Martenyi F, Treuer T, Gau SS, Hong SD, Palaczky M, Sˇuba J, Tiberiu M, Uhlıkova P, Xu T, Zoroglu S, Gadow KD, Walton R, Harrison G: Attention-deficit/hyperactivity disorder diagnosis, co-morbidities, treatment patterns, and quality of life in a pediatric population in central and eastern Europe and Asia. J Child Adolescent Psychopharmacol 2009, 19(4):363-76.
• [27]Saylor K, Williams DW, Schuh KJ, Wietecha L, Greenbaum M: Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. Curr Med Res Opin 2010, 26(9):2087-95.